Retronectin®-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: Tissue culture bag critically determines cell yield

Cytotherapy

Volumn 10, Issue 4, 2008, Pages 406-416

  Lamers, C H J ^a   van Elzakker, P ^a   van Steenbergen, S C L ^a   Sleijfer, S ^a   Debets, R ^a   Gratama, J W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adoptive immunotherapy; Culture bags; Gene transduction; Good manufacturing practice; T cells

Indexed keywords

FIBRONECTIN; RECOMBINANT FIBRONECTIN FRAGMENT; RECOMBINANT PROTEIN; RETROVIRUS VECTOR;

ARTICLE; CD3+ CD4+ T LYMPHOCYTE; CD3+ CD8+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CELL CULTURE BAG; CONTAINER; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DENDRITIC CELL; EFFECTOR CELL; GOOD MANUFACTURING PRACTICE; HELPER CELL; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRAL GENE DELIVERY SYSTEM; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL CULTURE; CULTURE TECHNIQUE; CYTOLOGY; CYTOTOXICITY; EVALUATION; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; INSTRUMENTATION; KIDNEY CARCINOMA; MATERIALS TESTING; METABOLISM; METHODOLOGY; PHYSIOLOGY; RETROVIRUS;

ANIMALS; CARCINOMA, RENAL CELL; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MATERIALS TESTING; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 47249164767     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240801982961     Document Type: Article

References (21)

1. Lamers, CH, van de Griend, RJ Braakman, E. et al. (1992) Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int J Cancer, 51, pp. 973-979.
2. Robinet, E., Certoux, JM Ferrand, C. et al. (1998) A closed culture system for the ex vivo transduction and expansion of human T lymphocytes. J Hematother, 7, pp. 205-215.
3. Lamers, CH, Willemsen, RA Luider, BA et al. (2002) Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther, 9, pp. 613-623.
4. Tran, CA, Burton, L. Russom, D. et al. (2007) Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: An approach to improving product safety, composition, and production capacity. J Immunother, 30, pp. 644-654.
5. Parker, LL, Do, MT Westwood, JA et al. (2000) Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther, 11, pp. 2377-2387.
6. Ma, Q., Safar, M. Holmes, E. et al. (2004) Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate, 61, pp. 12-25.
7. Ayuk, F., Li, Z. Kuhlcke, K. et al. (1999) Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements. Gene Ther, 6, pp. 1788-1792.
8. Pollok, KE, Hanenberg, H. Noblitt, TW et al. (1998) High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J Virol, 72, pp. 4882-4892.
9. Hanenberg, H., Xiao, XL Dilloo, D. et al. (1996) Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med, 2, pp. 876-882.
10. Lamers, C., van Elzakker, P. Langeveld, S. et al. (2006) Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for immunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. Cytotherapy, 8, pp. 542-553.
11. Bondanza, A., Valtolina, V. Magnani, Z. et al. (2006) Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood, 107, pp. 1828-1836.
12. Chinen, J., Davis, J. De Ravin, SS et al. (2007) Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood, 110, pp. 67-73.
13. Yuan, J., Kendle, R. Ireland, J. et al. (2007) Scalable expansion of potent genetically modified human Langerhans cells in a closed system for clinical applications. J Immunother, 30, pp. 634-643.
14. Lamers, CH, Sleijfer, S. Vulto, AG et al. (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol, 24, pp. 20-22.
15. Lamers, CHJ, Elzakker, P. Luider, BA et al. (2008) Retroviral vectors for clinical immunogene therapy are stable for up to 9 years. Cancer Gene Ther, 15, pp. 268-274.
16. Uemura, H., Okajima, E., Debruyne, FMJ and Oosterwijk, E. (1994) Internal image antiidiotype antibodies related to renal-cell carcinoma-associated antigen G250. Int J Cancer, 56, pp. 609-614.
17. Lamers, CH, Willemsen, RA van Elzakker, P. et al. (2006) Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: Implications for clinical immunogene therapy of cancer. Cancer Gene Ther, 13, pp. 503-509.
18. Bunnell, BA, Muul, LM Donahue, RE et al. (1995) High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci USA, 92, pp. 7739-7743.
19. + T lymphocytes. Gene Ther, 3, pp. 695-705.
20. Zhou, P., Lee, J., Moore, P. and Brasky, KM. (2001) High-efficiency gene transfer into rhesus macaque primary T lymphocytes by combining 32 degrees C centrifugation and CH-296-coated plates: Effect of gene transfer protocol on T cell homing receptor expression. Hum Gene Ther, 12, pp. 1843-1855.
21. Murray, L., Luens, K. Tushinski, R. et al. (1999) Optimization of retroviral gene transduction of mobilized primitive hematopoietic progenitors by using thrombopoietin, Flt3, and Kit ligands and RetroNectin culture. Hum Gene Ther, 10, pp. 1743-1752.